BRIEF-Avenue Says Dosed First Patient in Phase 3 Safety Trial of IV Tramadol [Reuters]
Avenue Therapeutics, Inc. (ATXI)
Last avenue therapeutics, inc. earnings: 8/14 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.avenuetx.com/investors/investors-home/default.aspx
Company Research
Source: Reuters
BRIEF-Avenue Says Dosed First Patient in Phase 3 Safety Trial of IV Tramadol | Reuters Reuters Staff 1 Min Read Jan 2 (Reuters) - Avenue Therapeutics Inc: * AVENUE THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 3 SAFETY TRIAL OF INTRAVENOUS TRAMADOL FOR THE MANAGEMENT OF POSTOPERATIVE PAIN * AVENUE THERAPEUTICS INC - COMPANY EXPECTS TO INITIATE A SECOND PHASE 3 TRIAL IN PATIENTS FOLLOWING ABDOMINOPLASTY SURGERY IN Q3 OF 2018 * AVENUE THERAPEUTICS- EVALUATING IV TRAMADOL IN PHASE 3 TRIAL IN PATIENTS FOLLOWING BUNIONECTOMY SURGERY, EXPECTS TO REPORT TOPLINE DATA IN Q2,2018 Source text for Eikon: Further company coverage: All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. Š 2018 Reuters. All Rights Reserved. BRIEF-Avenue Says Dosed First Patient in Phase 3 Safety Trial of IV Tramadol Jan 2 (Reuters) - Avenue Therapeutics Inc: * AVENUE THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 3 SAFETY TRIAL OF INTRAVENOUS TRA
Show less
Read more
Impact Snapshot
Event Time:
ATXI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATXI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATXI alerts
High impacting Avenue Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATXI
News
- Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024GlobeNewswire
- Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights [Yahoo! Finance]Yahoo! Finance
- Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate HighlightsGlobeNewswire
- Avenue Therapeutics Receives Positive Listing Determination from NasdaqGlobeNewswire
- Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual MeetingGlobeNewswire
ATXI
Sec Filings
- 4/17/24 - Form 4
- 4/17/24 - Form SC
- 3/29/24 - Form 8-K
- ATXI's page on the SEC website